Palbociclib


CAS No. : 571190-30-2

(Synonyms: PD 0332991)

571190-30-2
Price and Availability of CAS No. : 571190-30-2
Size Price Stock
5mg $60 In-stock
10mg $84 In-stock
50mg $108 In-stock
100mg $132 In-stock
200mg $168 In-stock
500mg $312 In-stock
1g $499 In-stock
5 g Get quote
10 g Get quote
We match the lowest price on market.

We offer a substantial discount on larger orders, please inquire via sales@chemexpress.cn

or Fax: (86)21-58955996

Inquiry for price and availability only. Please place your order via our email or fax.

Cat. No. : HY-50767
M.Wt: 447.53
Formula: C24H29N7O2
Purity: >98 %
Storage: at 20℃ 2 years
Solubility: DMSO: 0.2 mg/mL (Need ultrasonic or warming)
Introduction of 571190-30-2 :

Palbociclib is a highly specific inhibitor of Cdk4 (IC50=11 nM) and Cdk6 (IC50=16 nM), having no activity against a panel of 36 additional protein kinases. IC50 & Target: IC50: 11 nM (Cdk4), 16 nM (Cdk6)[1] In Vitro: The IC50 of Palbociclib (PD 0332991) for reduction of retinoblastoma (Rb) phosphorylation at Ser780 in MDA-MB-435 breast carcinoma cells is 66 nM. Palbociclib is equally effective at reducing Rb phosphorylation at Ser795 in this tumor with an IC50 of 63 nM, and similar effects on both Ser780 and Ser795 phosphorylation are obtained in the Colo-205 colon carcinoma[1]. The MP-MRT-AN (AN), KP-MRT-RY (RY), G401, and KP-MRT-NS (NS) cell lines are effectively inhibited by Palbociclib (PD) in a concentration-dependent manner in a WST-8 assay. The IC50s are 0.01 ?M, 0.01 ?M, 0.06 ?M, and 0.6 ?M, respectively. In contrast, the KP-MRT-YM (YM) cell line is resistant to Palbociclib (IC50>10 ?M). The flow cytometry results show that Palbociclib at concentrations between 0 to 1.0 ?M induces G1 arrest in the AN, RY, G401 and NS cell lines in a concentration-dependent manner, but has no effect on YM cells. The BrdU incorporation results are consistent with the WST-8 and flow cytometry results: PD reduces BrdU incorporation (indicating G1 arrest) in the AN, RY, G401 and NS cell lines, but not in the YM cell line. Palbociclib, even at a concentration of 0.05 ?M, significantly reduces BrdU incorporation in the AN, RY, and G401 cell lines (p<0.05)[2]. In Vivo: Palbociclib (PD 0332991) exhibits significant antitumor efficacy against multiple human tumor xenograft models. In mice bearing Colo-205 colon carcinoma xenografts (p16 deleted), daily p.o. dosing for 14 days with Palbociclib (150 or 75 mg/kg) produces rapid tumor regressions and a corresponding tumor growth delay of ~50 days with >1 log of tumor cell kill at the highest dose tested. At 37.5 mg/kg, the tumor slowly regressed during treatment. Even at doses as low as 12.5 mg/kg, a 13-day growth delay is obtained indicating a 90% inhibition of tumor growth rate. Likewise, robust antitumor activity is seen in the MDA-MB-435 breast carcinoma (p16 deleted) where complete tumor stasis is apparent at 150 mg/kg and some cell kill is evident at the highest dose[1].

Your information is safe with us.